Drug Search Results
More Filters [+]

Tetryzoline

Alternative Names: tetryzoline
Latest Update: 2021-08-31
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: ADRA1 Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Bulgaria | Canada | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | Greece | Hong Kong | Hungary | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Malta | Mexico | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tetryzoline

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title